neurodegenerative disease therapy (ALviva/Schwarz)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameneurodegenerative disease therapy (ALviva/Schwarz)
Drug Alias NameR-2HpcAcR-2HMPSPM-914R-2HPA
ClassificationSmall molecules
Mechanisms of ActionApoptosis inhibitors
TargetsUpdating
Therapy Area/IndicationsNerve DegenerationAmyotrophic Lateral SclerosisAlzheimer Disease +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaGermany
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesALviva Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesALviva Biopharmaceuticals IncUcb Pharma Gmbh
Active IndicationsN/A
Inactive IndicationsNerve DegenerationAmyotrophic Lateral SclerosisAlzheimer Disease +[5] 

Other Information

ATC CodeN/A
Related LinksN/A